ATTR-CM Treatment Challenges: CardioPODCAST 5x02

With the collaboration of:

In cardiac transthyretin (TTR) amyloidosis, the heart is progressively compromised by the extracellular accumulation of amyloid, a process that alters the form and function of the myocardium. This disorder has come to occupy a prominent place in clinical practice, mainly because it is increasingly recognized in older people with heart failure and preserved ejection fraction.

The therapeutic approach today focuses on agents that stabilize TTR, with tafamidis as the reference treatment and the recent arrival of acoramidis, a new drug whose relevance and characteristics we will analyze in today’s episode.

M.ª Luisa Peña Peña, Juan José Rodríguez Arias and Fernando Domínguez Rodríguez discuss with Felipe Díez del Hoyo in CardioPODCAST the aspects to take into account about this treatment.